Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Fuenlabrada – page 3

47 clinical trials in Fuenlabrada, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Fuenlabrada at a glance
47
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

47 trials in Fuenlabrada

Open in trial search

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Breast cancer+3

Not recruiting

Study of romiplostim for treating low platelet counts caused by chemotherapy in adults with non-small cell lung cancer, ovarian cancer, or breast cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Study of Atezolizumab, Trastuzumab, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Solti Group

Study on Budesonide Tablets for Treating Eosinophilic Esophagitis in Adults

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Breast cancer

Not recruiting

Study on Palbociclib and Drug Combination for Patients with Hormone Receptor Positive, HER2-Positive Metastatic Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Alliance Foundation Trials LLC

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Fuenlabrada

What the registry says about research in the country

01 Inflammatory Bowel Disease Research

Groundbreaking studies focusing on Crohn's Disease and Ulcerative Colitis treatments, evaluating new therapeutic approaches for patients with moderate to severe conditions.

  • Novel drug evaluations
  • Treatment resistance studies
  • Long-term therapy assessment

Multiple clinical trials testing innovative medications including RO7790121, obefazimod, and mirikizumab.

02 Oncology Studies

Comprehensive research into various types of breast cancer, particularly focusing on HER2-positive and hormone receptor-positive variants, along with studies in non-small cell lung cancer.

  • Targeted therapies
  • Combination treatments
  • Metastatic disease management

Evaluating breakthrough treatments including trastuzumab derivatives and novel therapeutic combinations.

03 Dermatological Conditions

Innovative research in atopic dermatitis, hand eczema, and alopecia areata, examining new treatment options for patients with moderate to severe symptoms.

  • Systemic treatments
  • Pediatric applications
  • Long-term efficacy studies

Testing advanced therapies including tralokinumab and upadacitinib for various skin conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.